Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T05:29:15.589Z Has data issue: false hasContentIssue false
  • English
  • Français

Profiles of the pharmacologic response of positive and negative symptoms in schizophrenia

Published online by Cambridge University Press:  28 April 2020

D. Pickar ,
A. Breier ,
O.M. Wolkowitz  and
C. Pato
D. Pickar*
Affiliation:
Section on Clinical Studies, Clinical Neuroscience Branch, National Institute of Mental Health, BLDG 10, RM 4N212, 9000 Rockville Pike, Bethesda, MD20892
A. Breier
Affiliation:
Section on Clinical Studies, Clinical Neuroscience Branch, National Institute of Mental Health, BLDG 10, RM 4N212, 9000 Rockville Pike, Bethesda, MD20892
O.M. Wolkowitz
Affiliation:
University of California (San Francisco), Dept Psychiatry, San Francisco, CA
C. Pato
Affiliation:
Section on Clinical Studies, Clinical Neuroscience Branch, National Institute of Mental Health, BLDG 10, RM 4N212, 9000 Rockville Pike, Bethesda, MD20892
*
Corresponding author: Correspondance à adresser à: David Pickar, M.D. Chief, Section on Clinical Studies, Clinical Neuroscience Branch, NIMH, NIH Bldg 10, Rm 4N212, 9000 Rockville Pike, Bethesda, MD 20892 (USA)
Get access

Summary

The delineation of the symptoms of schizophrenia into positive and negative types has been an important trend in psychiatric research over the past decade. This approach reflects renewed interests in clinical description and in developing etiologic hypotheses. The responsivity of positive and negative symptoms to neuroleptic and other pharmacotherapies, an issue of considerable clinical and research importance, however, remain in controversy.

We have observed that double-blind fluphenazine administration to 19 schizophrenic inpatients who had been maintained free from neuroleptic treatment for an extended period of time resulted in significant decreases in both positive as well as negative symptoms. The time course of symptom change differed, however, and the change in symptoms was not correlated, suggesting that the underlying pathophysiologies of positive and negative symptoms are only partially overlapping. The relative balance between positive and negative symptoms in individual patients, a putative schizophrenia trait characteristic, was found to be significantly altered by neuroleptic treatment, raising questions about the reliability of this classification approach.

In longitudinal studies in which plasma levels of the dopamine metabolite, homovanillic acid (HVA), were measured, change in negative symptoms associated with neuroleptic withdrawal and treatment were correlated, respectively, with changes in levels of plasma HVA. These data further support a relationship between negative symptoms and dopaminergic function. In addition to neuroleptic-induced reductions in negative symptoms, the augmentation of neuroleptic antipsychotic effects by the triazolobenzodiazepine, alprazolam, includes improvement in negative and positive symptoms in responsive patients.

These data including longitudinal studies of individual patients suggest that negative as well as positive symptoms respond to pharmacologic intervention. The clinical and research implications of these findings are discussed.

Résumé

Résumé

La division des symptômes de la schizophrénie en deux types, positif et négatif, a été un aspect important de la recherche en psychiatrie ces dernières années. Cette approche est le reflet d'intérêts nouveaux dans la description clinique et le développement d’hypothèses étiologiques. La réponse des symptômes positifs et négatifs aux neuroleptiques et autres thérapeutiques pharmacologiques, d’importance considérable sur le plan clinique et de la recherche, reste cependant controversée.

Nous avons observé que l'administration en double aveugle de fluphênazine à 19 schizophrènes hospitalisés, non soumis à un traitement aux neuroleptiques pendant une longue période, a induit une diminution significative des symptômes aussi bien positifs que négatifs. L’évolution des symptômes était cependant variable, et les symptômes n’étaient pas corrélés entre eux, suggérant que les pathophysiologies sous-jacentes ne se recoupent que partiellement. L’équilibre relatif entre symptômes positifs et négatifs chez chaque sujet pris individuellement, qui était une caractéristique possible du type de schizophrénie, s’est révélée significativement modifiée par le traitement neuroleptique, mettant en question la fiabilité de cette classification.

Les études longitudinales des taux plasmatiques du métabolite de la dopamine, l’acide homovanillique (HVA), indiquent que les modifications des symptômes négatifs associés au traitement neuroleptique ou à son arrêt sont corrélés avec les variations des taux d'HVA plasmatique. Ces données sont en faveur d'une relation entre les symptômes négatifs et la fonction dopaminergique. La réduction des symptômes négatifs induite par les neuroleptiques jointe à l'augmentation des effets antipsychotiques des neuroleptiques par la triazolobenzodiazépine, l’alprazolam, améliore les symptômes négatifs et les symptômes positifs chez les patients répondeurs.

Ces résultats, en particulier les études longitudinales chez des patients individuels, suggèrent que les symptômes, tant négatifs que positifs, répondent à la pharmacologie. Les implications sur le plan clinique et de la recherche sont discutées.

Keywords

Negative symptomsPositive symptomsSchizophreniaDopamineNeurolepticsAlprazolamSymptômes déficitairesSymptômes productifsSchizophrénieDopamineNeuroleptiquesAlprazolam
Type
Research Article
Information
Psychiatry and Psychobiology , Volume 2 , Issue 4 , 1987 , pp. 277 - 287
Copyright
Copyright © European Psychiatric Association 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References/Bibliographie

Abrams, R., Taylor, M.A. - A rating scale for emotional blunting. Am J Psychiatry 1978; 135: 229.Google ScholarPubMed
American Psychiatric Association Committee on Nomenclature and Statistics - Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed. American Psychiatric Association, Washington, DC, 494 pp., 1980.Google Scholar
Andreasen, N.C. - Negative symptoms in schizophrenia: definition and reliabilily. Arch Gen Psychiatry 1982; 39: 784–788.CrossRefGoogle Scholar
Andreasen, N.C. - Scale for the Assessment of Negative Symptoms (SANS), University of Iowa, Iowa City, 1981.Google Scholar
Andreasen, N.C.Positive versus negative schizophrenia: a critical evaluation. Schizophr Bull 1985; 11: 380–389.CrossRefGoogle Scholar
Andreasen, N.C., Olsen, S. - Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39: 789–794.CrossRefGoogle Scholar
Andreasen, N.C., Olsen, S.A., Denvert, J.W., Smith, M.R.Ventricular enlargement in schizophrenia: relationship to positive and negative svmptoms. Am J Psychiatry 1982; 139: 297–302.Google Scholar
Bacopoulos, N.G., Hattox, S.E., Roth, R.H. - 3,4- Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 1979; 56: 225–236.CrossRefGoogle ScholarPubMed
Bacopoulos, N.G., Redmond, D.H., Baulu, J., Roth, R.H. - Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (Vervet monkey). J Pharmacol Exp Ther 1980; 212: 1–5.Google Scholar
Bannon, M.J., Roth, R.H. - Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 1983; 35: 53–68.Google ScholarPubMed
Breier, A., Wolkowitz, O.M., Doran, A.R., Roy, A., Boronow, J., Hommer, D.W., Pickar, D. - Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987 (in press).Google Scholar
Bunney, B.S., Grace, A.A. - Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978; 23: 1715–1728.CrossRefGoogle ScholarPubMed
Bunney, W.E. Jr., Hamburg, D.A. - Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 1963; 9: 280–294.CrossRefGoogle ScholarPubMed
Casey, J.F., Bennett, I.F., Lindley, C.J., Hollister, L.E., Gordon, M.H, Springer, N.N. - Drug therapy in schizophrenia: a controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital and placebo. Arch Gen Psychiatry 1960; 2: 210–220.CrossRefGoogle ScholarPubMed
Chang, W.H, Sheinin, M., Burns, R.S., Linnoila, M. - Rapid and simple determination of homovanillic acid in plasma using hith performance liquid chromatography with electrochemical detection. Acta Pharmacol Toxicol 1983; 53; 275–279.CrossRefGoogle Scholar
Cole, J.O., Klerman, G.L., Goldberg, S.C. - Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246–261.Google Scholar
Creese, I., Burth, D.R., Snyder, S.H. - Dopamine receptor binding predicts clinical and pharmacologie potencies of antischizophrenic drugs. Science 1976; 192: 481–483.CrossRefGoogle Scholar
Crow, T.J. - Molecular pathology of schizophrenia: more than one disease process. Br Med J 1980; 280: 1–9.CrossRefGoogle ScholarPubMed
Crow, T.J. - The two-syndrome concept: origins and current concepts. Schizophr Bull 1985; 11: 471–486.CrossRefGoogle Scholar
Csernansky, J.G., Lombrozo, L., Gulevich, G.D, Hollister, L.E. - Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study. J Clin Psychopharmacol 1984; 4: 349–352.CrossRefGoogle ScholarPubMed
Dawson, G.W., Jue, S.G., Brogden, R.N. - Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 1984; 27: 132–147.CrossRefGoogle ScholarPubMed
Donaldson, S.R., Gelenberg, A.J., Baldessarini, R.J. - The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 1983; 9: 504–527.CrossRefGoogle ScholarPubMed
Doran, A.R., Boronow, J., Weinberger, D.R., Wolkowitz, O.M., Breier, A., Pickar, D. - Structural brain pathology in schizophrenia revisited: prefrontal cortex pathology is inversely correlated with CSF levels of homovanillic acid. Neuropsychopharmacology, in press.Google Scholar
Goldberg, S.C. - Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985; 11: 453–456.CrossRefGoogle ScholarPubMed
Goldberg, S.C., Klerman, G.L., Cole, J.O. - Changes in schizophrenic psychopathology and ward behavior as a function of phenotiazine treatment. Br J Psychiatry 1965; 111: 120–133.CrossRefGoogle Scholar
Gould, R.J., Murphy, K.M.M., Reynolds, I.J., Snyder, S.H. - Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci (USA) 1983; 80: 5122–5125.CrossRefGoogle ScholarPubMed
Henrichs, D.W., Hanlon, T.E., Carpenter, W.T. - The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10; 388–398.CrossRefGoogle Scholar
Johnstone, E.C., Crow, T.J., Firth, C.D., Husband, J., Kreel, L. - Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 1976; 2: 924–926.CrossRefGoogle ScholarPubMed
Johnstone, E.C., Crow, T.J., Firth, C. D., Carney, M.W.P., Price, J.S. - Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978; 1: 848–851.CrossRefGoogle ScholarPubMed
Kendler, K.S., Heninger, G.R., Roth, R.H - Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci 1982; 30: 2063–2069.CrossRefGoogle ScholarPubMed
Klein, D.F. - Importance of psychiatric diagnosis in prediction of clinical drug effect. Arch Gen Psychiatry 1967; 16: 118–126.CrossRefGoogle Scholar
Lapierre, Y.D. - A controlled study of penfluridol in the treatment of schizophrenia. Am J Psychiatry 1978; 135: 256–259.Google ScholarPubMed
Lapierre, Y.D., Lavallee, J. - Pimozide and the social behavior of schizophrenics. Curr Ther Res 1975; 18: 181–188.Google ScholarPubMed
Lewine, R.R.J., Fogg, L., Meltzer, H.Y. - Assessment of negative and positive symptoms in schizophrenia. Schizophr Bull 1983; 9: 368–378.CrossRefGoogle Scholar
Lingjaerde, O. - Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatr Scand 1982; 65: 339–354.CrossRefGoogle ScholarPubMed
May, P.R., Tuma, A.H, Dixon, W.J. - Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981; 38: 776–784.CrossRefGoogle ScholarPubMed
Nesteros, J.N. - Benzodiazepines in schizophrenia: a need for reassessment. Pharmacopsychiatry 1980; 15: 171–179.CrossRefGoogle Scholar
Overall, J.E., Gorham, D.E. - The Brief Psychiatric Rating Scale. Psychol Rep 1961; 10: 799–812.CrossRefGoogle Scholar
Pickar, D. - Neuroleptics, dopamine, and schizophrenia. Psychiatr Clin North Am 1986; 9: 35–48.CrossRefGoogle Scholar
Pickar, D., Labarca, R., Doran, A.R., Wolkowitz, O.M., Roy, A., Breier, A., Linnoila, M., Paul, S.M. - Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 1986; 43: 669–676.CrossRefGoogle ScholarPubMed
Pickar, D, Labarca, R., Linnoila, M., Roy, A., Hommer, D., Everett, D., Paul, S.M. - Neurolepticinduced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 1984; 225: 954–957.CrossRefGoogle Scholar
Pickar, D, Wolkowitz, O.M., Doran, A.R., Labarca, R., Roy, A., Breier, A., Narang, P.K. - Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987; 44: 113–118.CrossRefGoogle ScholarPubMed
Pycock, C.J., Kerwin, R.W., Carter, C.J. - Effect of lesion of cortical dopamine terminals on subcortical dopamine in rats. Nature 1980; 286: 74–77.CrossRefGoogle ScholarPubMed
Roth, R.H. - Neuroleptics: Functional Chemistry, In: Coyle, J.T., Enna, S.J. eds.: Neuroleptics: Neurochemical, Behavioral and Clinical Perspectives, Raven Press, New York, 1983.Google Scholar
Seeman, P., Lee, T., Chau-Wong, M., Wong, K. - Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–719.CrossRefGoogle ScholarPubMed
Shelton, R.C., Doran, A.R., Pickar, D., Weinberger, D.R. - Cerebral structural pathology in schizophrenia: evidence for a selective prefrontal cortical defect. Am J Psychiatry 1987 (in press).Google Scholar
Shelton, R.C., Weinberger, D.R. - X-ray Computerized Tomography Studies in Schizophrenia: A Review and Synthesis, In: Nasrallah, H.A., Weinberger, D.R. eds.: Handbook of Schizophrenia (Vol I), The Neurology of Schizophrenia, 207–250, Elsevier, New York, 1986.Google Scholar
Sternberg, D.E., Heninger, G.R., Roth, R.H. - Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. Life Sci 1983; 32: 2447–2452..CrossRefGoogle ScholarPubMed
Weinberger, D.R., Berman, K.F., Zec, R.F. - Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 1986; 43: 114–124.CrossRefGoogle ScholarPubMed
Weinberger, D.R., Torrey, E.F., Neophytides, A. - Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 1979; 36: 735–739.CrossRefGoogle ScholarPubMed
White, J.F., Wang, R.Y. - Differential effects of classical and atypical antipsychotic drugs on A9, and Al0 dopamine neurons. Science 1983; 221: 1054–1056.CrossRefGoogle Scholar
Wolkowitz, O.M., Breier, A., Doran, A., Kelsoe, J.Lucas, P., Paul, S.M., Pickar, D. - Alprazolam augmentation of neuroleptic antipsychotic effects in schizophrenia (Submitted, 1987).Google Scholar
Wolkowitz, O.M., Pickar, D., Doran, A.R., Breier, A., Tarell, J., Paul, S.M. - Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 1986; 143: 85–87.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.